Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders

The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.

Inclusion Criteria:

• 18-75 years of age
• Meets criteria for Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified or Borderline Personality Disorder
• Ability to speak, read and understand the English Language and provide written informed consent

Exclusion Criteria:

• Current, unstable and significant medical condition or illness
• History of Thyroid disorder, seizure disorder, tumors or other CNS condition that predisposes the patient to risk of seizure
• Pregnant or lactating females
• Abnormal clinical laboratory test results
• Intolerance or hypersensitivity to SSRIs or lithium
• History or current diagnosis of bipolar mood disorder, psychosis, schizophrenia or dementia
• Certain mediations my not be used prior or during the study